NANOFH Stock Overview
Engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nanoform Finland Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.46 |
| 52 Week High | €3.50 |
| 52 Week Low | €1.05 |
| Beta | 0.80 |
| 11 Month Change | 12.14% |
| 3 Month Change | -21.67% |
| 1 Year Change | -10.15% |
| 33 Year Change | -77.88% |
| 5 Year Change | n/a |
| Change since IPO | -71.09% |
Recent News & Updates
Recent updates
We Think Nanoform Finland Oyj (HEL:NANOFH) Can Afford To Drive Business Growth
Nov 07
We're Not Very Worried About Nanoform Finland Oyj's (HEL:NANOFH) Cash Burn Rate
Apr 28We're Hopeful That Nanoform Finland Oyj (HEL:NANOFH) Will Use Its Cash Wisely
Nov 04Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth
Jan 25What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition
Dec 21Shareholder Returns
| NANOFH | FI Life Sciences | FI Market | |
|---|---|---|---|
| 7D | -4.7% | 0.5% | 0.3% |
| 1Y | -10.2% | 6.9% | -1.9% |
Return vs Industry: NANOFH underperformed the Finnish Life Sciences industry which returned 6.6% over the past year.
Return vs Market: NANOFH underperformed the Finnish Market which returned -2.8% over the past year.
Price Volatility
| NANOFH volatility | |
|---|---|
| NANOFH Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in FI Market | 7.0% |
| 10% least volatile stocks in FI Market | 2.7% |
Stable Share Price: NANOFH's share price has been volatile over the past 3 months compared to the Finnish market.
Volatility Over Time: NANOFH's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Finnish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 7 | Edward Haeggstrom | www.nanoform.com |
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharmaceutical and biotech industry in Europe and the United States. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients, as well as designs and develops nanoformed drug substance. It also offers STARMAP, as a secure online portal to perform large numbers of in-silico CESS experiments The company was founded in 2008 and is headquartered in Helsinki, Finland.
Nanoform Finland Oyj Fundamentals Summary
| NANOFH fundamental statistics | |
|---|---|
| Market cap | €124.88m |
| Earnings (TTM) | -€23.07m |
| Revenue (TTM) | €2.43m |
51.4x
P/S Ratio-5.4x
P/E RatioIs NANOFH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANOFH income statement (TTM) | |
|---|---|
| Revenue | €2.43m |
| Cost of Revenue | €521.04k |
| Gross Profit | €1.91m |
| Other Expenses | €24.98m |
| Earnings | -€23.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 78.54% |
| Net Profit Margin | -950.53% |
| Debt/Equity Ratio | 0% |
How did NANOFH perform over the long term?
See historical performance and comparison